Longitudinal recurrence risk of adjuvant cytotoxic chemotherapy and gefitnib in resected lung cancer: A combined analysis of phase III studies.

doi:10.1016/j.lungcan.2025.108437

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Longitudinal recurrence risk of adjuvant cytotoxic chemotherapy and gefitnib in resected lung cancer: A combined analysis of phase III studies.

Lung cancer (Amsterdam, Netherlands) - 1 Mar 2025

Akamatsu Hiroaki, Nishikawa Tomomi, Takeda Yuriko, Misumi Toshihiro, Aoki Tadashi, Shoda Hiroyasu, Yamashita Motohiro, Sakakura Noriaki, Daga Haruko, Sugawara Shunichi, Okishio Kyoichi, Kenmotsu Hirotsugu, Yamamoto Nobuyuki, Tada Hirohito, Tsuboi Masahiro, Mitsudomi Tetsuya

Abstract excerpt

INTRODUCTION: In patients with completely resected non-small cell lung cancer, it is not fully understood whether the longitudinal recurrence risk differs by the types of adjuvant treatment in EGFR-mutated patients. METHODS: Individual data from two phase 3 trials (JIPANG and IMPACT) were collected and patients were categorized into three groups (A [EGFR wild-type, chemotherapy: n = 299], B [EGFR mutant,...

Read the complete abstract on PubMed

Topics

Adult
Aged
Female
Humans
Male

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Middle Aged

Antineoplastic Combined Chemotherapy Protocols

Carcinoma, Non-Small-Cell Lung

Chemotherapy, Adjuvant

Clinical Trials, Phase III as Topic

ErbB Receptors

Gefitinib

Lung Neoplasms

Mutation

Neoplasm Recurrence, Local

Source

Open in PubMed

Identifiers

PMID: 39938189
DOI: 10.1016/j.lungcan.2025.108437

Genes

EGFR
IMPACT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 25 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Longitudinal recurrence risk of adjuvant cytotoxic chemotherapy and gefitnib in resected lung cancer: A combined analysis of phase III studies.PMID 39938189Read ↗

EGFR Mutations and Recurrence Outcomes in Resected Non-Small Cell Lung Cancer: An Updated 2015-2025 Systematic Review and Meta-Analysis.Semantic proximity Read ↗

RADAR CARE Study: A Multicenter Deep Learning Model for Real-Time Prediction of Recurrence in Early-Stage Non–Small Cell Lung Cancer Using a Multimodal ApproachSemantic proximity Read ↗

EGFR mutation status, treatment patterns, and outcomes in resectable early-stage non-small cell lung cancer prior to adjuvant EGFR-TKI approval: An international real-world study.Semantic proximity Read ↗

Relative efficacies of EGFR-TKIs and immune checkpoint inhibitors for treatment of recurrent non-small cell lung cancer after surgerySemantic proximity Read ↗

Dynamic recurrence risk and adjuvant chemotherapy benefit prediction by ctDNA in resected NSCLC.Semantic proximity Read ↗

Clinical, Pathologic, and Molecular Prognostic Factors in Patients with Early-Stage EGFR-Mutant NSCLC.Semantic proximity Read ↗

Optimal Treatment Strategy for Oligo-Recurrence Lung Cancer Patients With Driver MutationsSemantic proximity Read ↗

Targeted Next-Generation Sequencing Analysis for Recurrence in Early-Stage Lung Adenocarcinoma.Semantic proximity Read ↗

Genetic Alterations and Risk Factors for Recurrence in Patients with Non-Small Cell Lung Cancer Who Underwent Complete Surgical ResectionSemantic proximity Read ↗

Prognostic potential of circulating tumor DNA detection at different time periods in resectable non-small cell lung cancer: Evidence from a meta-analysis.Semantic proximity Read ↗

EGFR Mutation Impacts Recurrence in High-Risk Early-Stage Lung Adenocarcinoma in the IASLC Grading SystemSemantic proximity Read ↗

Prognostic factors for relapse-free survival in stage IB-IIIA primary lung adenocarcinoma by epidermal growth factor receptor mutation status.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.